Neurologia medico-chirurgica

Temozolomide works better in malignant brain tumors with 1p gene loss and MGMT gene methylation

Circadian Biology Weekly Brief ↗PubMed ↗DOI ↗

Updated

Abstract

Promoter methylation of the MGMT gene is associated with improved outcomes in 44 patients with recurrent malignant gliomas treated with temozolomide.

  • MGMT promoter methylation correlates positively with clinical response to temozolomide therapy.
  • Loss of heterozygosity (LOH) of 1p and 19q is associated with better responses to treatment.
  • Patients with LOH of 1p and MGMT promoter methylation may experience longer progression-free survival.
  • The findings suggest that LOH of 1p could be an important predictor of treatment outcomes alongside MGMT methylation.

Simplified

Full Text

Full text is available at the source.
View Full Text ↗

Related papers

Sep '10
Measuring MGMT Gene Control Region Methylation in Patients with Low-Grade Brain Tumors
cited by 20 papers
journal article
Sep '06
Links between DNA repair gene changes, chromosome deletions, and response to temozolomide in aggressive and returning oligodendroglioma tumors
top 1% journal
cited by 154 papers
clinical trial
Nov '11
Molecular markers linked to outcomes in aggressive brain tumors: a review of 77 patients from China
top 1% journal
cited by 37 papers
research support, non-u.s. gov't
Oct '10
IDH1 or IDH2 gene mutations linked to longer survival and better response to temozolomide in low-grade brain tumors
top 5% journal
cited by 445 papers
research support, non-u.s. gov't
Nov '10
Methylation of a DNA Repair Gene in Brain Tumors and Its Link to Other Molecular Changes: First Report from India and Challenges for Personalized Treatment
top 20% journal
cited by 33 papers
research support, non-u.s. gov't
Oct '13
How IDH1 mutation, MGMT gene methylation, and 1p19q gene deletion relate to outcomes in Japanese malignant brain tumor patients
top 30% journal
cited by 23 papers
journal article
Nov '08
Links between chromosome changes and levels of DNA repair, cell growth, and tumor markers in grade II and III brain tumors
top 10% journal
cited by 19 papers
research support, non-u.s. gov't
Sep '15
Blocking DNA-repair genes Ercc1 and Mgmt may improve temozolomide treatment in brain tumors
top 30% journal
cited by 26 papers
research support, non-u.s. gov't
Dec '10
Temozolomide chemotherapy after radiotherapy for growing low-grade brain tumors: molecular traits linked to treatment response
top 1% journal
cited by 59 papers
research support, non-u.s. gov't
Nov '08
MGMT Gene Methylation and Its Link to Temozolomide Response in Brain Tumor Models
top 20% journal
cited by 79 papers
research support, n.i.h., extramural

what lands in your inbox each week:

  • 📚7 fresh studies
  • 📝plain-language summaries
  • ✅direct links to original studies
  • 🏅top journal indicators
  • 📅weekly delivery
  • 🧘‍♂️always free

Recent issues from the circadian biology brief

issue #44
Sleeping late on weekends is independently linked to higher cardiovascular disease risk
yesterday7 studies
issue #43
A smartphone app cut mood episode recurrence 3.4x in people with depression and bipolar disorder
1 week ago7 studies
issue #42
Morning cancer immunotherapy linked to 49% vs 40% disease control rate in 969 patients
2 weeks ago7 studies
issue #41
Timing cancer treatment before 3pm nearly doubled survival in lung cancer patients
3 weeks ago7 studies
issue #40
Male mice lived 12% longer when they ate only during an 8-hour window at night
4 weeks ago7 studies
issue #38
Emergency doctors had 67% higher odds of chronic pain when working evening shifts vs. morning shifts
6 weeks ago7 studies
issue #36
Night owls show 77% higher risk of job burnout among firefighters
8 weeks ago7 studies
issue #35
Bacteria exposure resets your internal clock independently of immune responses
9 weeks ago7 studies
issue #34
Night owl teens got 47 minutes more sleep with bright light glasses
10 weeks ago7 studies
issue #33
Working out at your optimal time cuts blood pressure twice as much
11 weeks ago7 studies
explore the archive
See more issues from the circadian biology brief